about
Human atrial natriuretic factor and renin-aldosterone in paracetamol induced fulminant hepatic failure.Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction.Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac diseasePrognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.Localisation of atrial natriuretic peptide immunoreactivity in the ventricular myocardium and conduction system of the human fetal and adult heartThe effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: a longitudinal study.Secretion of atrial natriuretic peptide from the heart in man.Atrial natriuretic peptide in spontaneous tachycardiasPulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs.Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patientsEffect of beta-adrenoceptor blockade on atrial natriuretic peptide levels during exercise in angina pectorisClearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog.Diagnosis of heart failureVascular tone in heart failure: the neuroendocrine-therapeutic interfaceAtrial natriuretic peptides: clues to their physiological and clinical importance.The treatment of heart failure--what next?A comparison of the vasodilator responses to atrial peptides in the pulmonary and renal arteries of the pig in vitro.Neuroendocrine excitation in heart failure.Physiological hypertrophy of the heart and atrial natriuretic peptide during rest and exercise.Vascular responses to local atrial natriuretic peptide infusion in man.
P2860
Q28326416-D369B206-224D-4AAC-98C7-5A41DFF5F6BDQ28378632-2B610978-296F-45A4-BEE0-6E86195DBD2AQ33612779-0ED660CC-A3FC-4D8E-B844-60EA03C2EC57Q33613525-EC52C3A1-46AB-42BF-B893-3ADC6C512E26Q33614319-31AEF40B-AFC7-44EB-A9CA-BEE311F5D382Q33999739-30499952-3FB0-4E49-A5FA-DDE5269F29E1Q34117550-89CC7FC5-B2C9-4CAC-AB3B-51E93BF50411Q34118343-FEA4E5D8-8E35-4218-9DFE-652648CA9978Q34118505-05464717-AD68-430C-B920-EB703864C16FQ34187999-D65D39BC-BC4E-4B8C-89FC-1FAF380DBFDFQ34402895-8641A70B-4EFF-41D1-AF86-FED4E181974AQ34403589-A92B56D5-055A-474C-9947-9F537DE6904FQ34566859-0DA76657-7863-4E41-AA3E-0CE89D2F3515Q35578873-51996DB3-8E09-40C5-83C8-5B98DA4343D6Q36808117-22301933-9AE3-4202-A0F4-46052E784335Q39165774-0CF9EF82-1A9E-4CA6-A2D7-F2503FFBB608Q39493510-1A010C04-677D-4141-8A24-A8F4BC095A43Q42086145-00315171-AA01-4437-A5C3-FD5C8700AC23Q42102587-257AE8BD-D5FD-4E3D-80CD-C62CD7DC27CDQ42143543-8036DB98-8628-4DF8-8778-603A70F6B911Q43229256-5015E4CF-E1C2-443D-9EB0-24E6FFB4C2DB
P2860
description
1986 nî lūn-bûn
@nan
1986 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Plasma alpha natriuretic peptide in cardiac impairment.
@ast
Plasma alpha natriuretic peptide in cardiac impairment.
@en
Plasma alpha natriuretic peptide in cardiac impairment.
@nl
type
label
Plasma alpha natriuretic peptide in cardiac impairment.
@ast
Plasma alpha natriuretic peptide in cardiac impairment.
@en
Plasma alpha natriuretic peptide in cardiac impairment.
@nl
prefLabel
Plasma alpha natriuretic peptide in cardiac impairment.
@ast
Plasma alpha natriuretic peptide in cardiac impairment.
@en
Plasma alpha natriuretic peptide in cardiac impairment.
@nl
P2093
P2860
P1433
P1476
Plasma alpha natriuretic peptide in cardiac impairment.
@en
P2093
Cleland JG
McIntyre GD
Richards AM
Robertson JI
P2860
P304
P407
P577
1986-08-01T00:00:00Z